Comparison of multimodality treatment; 2 or 4 courses of Paclitaxel/CDDP or S1/CDDP followed by surgery for locally advanced gastric cancer, a randomized phase II trial (COMPASS).

Trial Profile

Comparison of multimodality treatment; 2 or 4 courses of Paclitaxel/CDDP or S1/CDDP followed by surgery for locally advanced gastric cancer, a randomized phase II trial (COMPASS).

Completed
Phase of Trial: Phase II

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs Cisplatin (Primary) ; Gimeracil/oteracil/tegafur (Primary) ; Paclitaxel (Primary)
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms COMPASS
  • Most Recent Events

    • 11 Oct 2016 Results of pharmacogenomic substudy (n=80) presented at the 41st European Society for Medical Oncology Congress.
    • 28 May 2016 Primary endpoint has not been met. (3-year overall survival (OS)), as per results published in the European Journal of Cancer.
    • 28 May 2016 Results published in the European Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top